Ahmed Koriesh on Comparison of Apixaban and Warfarin
Ahmed Koriesh, Director Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”How many patients have you seen with stroke or bleeding related to warfarin in LVAD patients?
A recent trial in LVAD patients compared apixaban with warfarin over 2 years:
Lower HRAEs (stroke, bleeding, thrombosis):
12.5% vs 43% (p=0.087)
Significantly fewer transfusions:
0.69 vs 4.82 EPPY (p<0.01)
Win ratio favored apixaban:
2.30 (95% CI 0.95–5.60)
Although underpowered, the signals consistently leaned toward apixaban with no excess thrombosis or mortality observed.
Bottom line:
Apixaban is showing a promise as a safe alternative to warfarin in selected LVAD patients — larger trials are needed before changing practice.”
Stay updated with Hemostasis Today.
-
Feb 21, 2026, 15:58Addressing Underdiagnosis and Care Inequities in Women and Girls with Bleeding Disorders – WFH
-
Feb 21, 2026, 15:49Sheharyar Raza: The Leaky Pipeline of AI and Machine Learning in Transfusion Medicine
-
Feb 21, 2026, 15:21Joanna Sadowska: Watching a Stem Cell Divide Reveals Life’s Blueprint
-
Feb 21, 2026, 14:43Gashaw Arega: Demonstrating Impact Through Blood Donation for Childhood Cancer
-
Feb 21, 2026, 14:42Travel Tips for Attending WFH 2026 World Congress in Kuala Lumpur
-
Feb 21, 2026, 13:56Tagreed Alkaltham: Transfusion Misidentification – When Identity Errors Become Fatal
-
Feb 21, 2026, 13:46Timothy Stalker: Differences Between Arterial and Venous Hemostasis
-
Feb 21, 2026, 13:36Augustina Isioma Ikusemoro: Strengthening Awareness and Prevention on World Anaemia Awareness Day
-
Feb 21, 2026, 13:20Mary Cushman: Novel Proteins Shed Light on the Mechanisms of VTE